The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
Christian, Sven
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. [electronic resource] - Leukemia 10 2019 - 2403-2415 p. digital
Publication Type: Journal Article
1476-5551
10.1038/s41375-019-0461-5 doi
Animals
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Cell Differentiation--drug effects
Cell Line, Tumor
Dihydroorotate Dehydrogenase
Enzyme Inhibitors--pharmacology
Female
HL-60 Cells
Humans
Leukemia, Myeloid, Acute--drug therapy
Leukemia, Promyelocytic, Acute--drug therapy
Mice
Mice, Inbred NOD
Mice, SCID
Oxidoreductases Acting on CH-CH Group Donors--antagonists & inhibitors
Pyrimidines--metabolism
THP-1 Cells
Translocation, Genetic--drug effects
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. [electronic resource] - Leukemia 10 2019 - 2403-2415 p. digital
Publication Type: Journal Article
1476-5551
10.1038/s41375-019-0461-5 doi
Animals
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Cell Differentiation--drug effects
Cell Line, Tumor
Dihydroorotate Dehydrogenase
Enzyme Inhibitors--pharmacology
Female
HL-60 Cells
Humans
Leukemia, Myeloid, Acute--drug therapy
Leukemia, Promyelocytic, Acute--drug therapy
Mice
Mice, Inbred NOD
Mice, SCID
Oxidoreductases Acting on CH-CH Group Donors--antagonists & inhibitors
Pyrimidines--metabolism
THP-1 Cells
Translocation, Genetic--drug effects